---
title: CRISPR Therapeutics (CRSP) — Wall Street analysts' targets, grades and estimates
canonical: https://sweetvaluelab.com/stocks/crsp/analysts
ticker: CRSP
as_of: 2026-11-02
sector: Healthcare
---
# CRISPR Therapeutics (CRSP) — Wall Street analysts

9 firms published a price target for CRSP in the last 12 months. Counting each firm once, at its latest, the median target is $60.00, 17% above the last close of $51.42 (Oct 30, 2026); the lowest is $50.00 and the highest $82.00.

These are the analysts' figures, quoted, not this site's. The site's own model value for CRSP is on the valuation page: https://sweetvaluelab.com/stocks/crsp/valuation.

## At a glance

| Figure | Value |
| --- | ---: |
| Median target (each firm's latest, last 12 months) | $60.00 |
| Median target vs last close | +17% |
| Firms with a target, last 12 months | 9 |
| Lowest – highest target | $50.00 – $82.00 |
| Current grades of 11 firms: positive / neutral / negative | 7 / 4 / 0 |
| Upgrades / downgrades, last 12 months | 0 / 0 |
| Consensus revenue growth, next 3 fiscal years | +428% a year |

## Each firm's latest target (last 12 months)

Newest first. Change is against the same firm's previous target; the last two columns are the target against the close on the day it was published and against the last close.

| Date | Firm | Target | Previous | Change | Vs price then | Vs price now | Report |
| --- | --- | ---: | ---: | ---: | ---: | ---: | --- |
| 2026-10-15 | UBS | $52.00 | $80.00 | −35% | +4% | +1% | https://thefly.com/ajax/news_get.php?id=4441877 |
| 2026-08-06 | Goldman Sachs | $55.00 | — | — | +5% | +7% | https://thefly.com/ajax/news_get.php?id=4404643 |
| 2026-07-08 | H.C. Wainwright | $80.00 | — | — | +32% | +56% | https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+CRISPR+Therapeutics+%28CRSP%29/26743997.html |
| 2026-06-11 | Morgan Stanley | $60.00 | $33.00 | +82% | +21% | +17% | https://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Assumes+CRISPR+Therapeutics+%28CRSP%29+at+Equalweight/26631691.html |
| 2026-05-13 | Bernstein | $56.00 | — | — | +6% | +9% | https://thefly.com/ajax/news_get.php?id=4353769 |
| 2026-05-11 | Evercore ISI | $76.00 | $74.00 | +3% | +37% | +48% | https://thefly.com/ajax/news_get.php?id=4351673 |
| 2026-02-14 | Chardan Capital | $76.00 | $74.00 | +3% | +43% | +48% | https://thefly.com/permalinks/entry.php/id4293256/9561286394/CRSP-Crispr-Therapeutics-price-target-raised-by--at-Chardan-heres-why |
| 2026-02-13 | Needham | $82.00 | — | — | +52% | +59% | https://thefly.com/permalinks/entry.php/id4292860/2163286394/CRSP-Crispr-Therapeutics-price-target-raised-by--at-Needham-heres-why |
| 2025-11-11 | RBC Capital | $50.00 | — | — | −8% | −3% | https://www.streetinsider.com/Analyst+Comments/CRISPR+Therapeutics+%28CRSP%29+PT+Raised+to+%2450+at+RBC+Capital/25587864.html |

## Current grades (each firm's latest, last 12 months)

| As of | Firm | Grade |
| --- | --- | --- |
| 2026-08-31 | Citizens | “Market Outperform” |
| 2026-08-31 | Needham | “Buy” |
| 2026-08-04 | Citigroup | “Buy” |
| 2026-07-08 | H.C. Wainwright | “Buy” |
| 2026-05-13 | Bernstein | “Market Perform” |
| 2026-03-17 | Piper Sandler | “Overweight” |
| 2026-02-17 | Chardan Capital | “Buy” |
| 2026-02-13 | Evercore ISI | “Outperform” |
| 2026-02-13 | TD Cowen | “Hold” |
| 2025-11-11 | Baird | “Neutral” |
| 2025-11-11 | RBC Capital | “Sector Perform” |

## Grade changes (last 24 months)

| Date | Firm | From | To | Action |
| --- | --- | --- | --- | --- |
| 2025-06-27 | Clear Street | “Buy” | “Hold” | downgrade |
| 2025-02-14 | Evercore ISI | “In Line” | “Outperform” | upgrade |

20 older changes are listed on the page.

## Consensus estimates by fiscal year

A reported year shows the company's revenue and GAAP diluted EPS with the consensus beside it; a later year shows the consensus average and its range. The analysts' EPS usually leaves items such as stock compensation out, so reported and estimated EPS are not like for like.

| Fiscal year | Status | Revenue | YoY | EPS | YoY | Consensus revenue | Consensus EPS | Analysts |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| 2023 | reported | $370.0M | +84762% | -$1.94 | — | $293.2M (reported +26% vs it) | -$2.92 | 18 |
| 2024 | reported | $35.0M | −91% | -$4.34 | — | $11.2M (reported +213% vs it) | -$5.16 | 19 |
| 2025 | reported | $3.5M | −90% | -$6.47 | — | $7.1M (reported −50% vs it) | -$6.21 | 17 |
| 2026 | estimate | $40.4M | +1052% | -$4.36 | — | $15.1M – $100.0M | -$5.53 – -$3.33 | 15 |
| 2027 | estimate | $138.6M | +243% | -$3.33 | — | $2.0M – $497.7M | -$4.99 – -$1.09 | 14 |
| 2028 | estimate | $518.0M | +274% | -$2.01 | — | $29.3M – $3.5B | -$7.08 – $9.62 | 12 |
| 2029 | estimate | $2.6B | +407% | $4.42 | — | $170.8M – $13.5B | -$0.95 – $28.14 | 10 |
| 2030 | estimate | $6.7B | +157% | $19.26 | +336% | $438.4M – $34.6B | -$4.15 – $122.60 | 6 |

---

Source: https://sweetvaluelab.com/stocks/crsp/analysts (SweetValueLab, free, no account). Targets, grades and estimates are the analysts' own, quoted from Financial Modeling Prep's analyst feeds; reported figures from the company's statements. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.